| Dr Christopher O Baldwin, MD | |
|
1337 S Sam Houston Blvd, Houston, MO 65483 | |
| (417) 967-5639 | |
| (417) 967-5667 |
| Full Name | Dr Christopher O Baldwin |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 46 Years |
| Location | 1337 S Sam Houston Blvd, Houston, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164483921 | NPI | - | NPPES |
| 26D2006074 | Other | MO | CLIA |
| 268653 | Other | MO | MEDICARE OSCAR |
| 26D0889777 | Other | MO | CLIA |
| P01604050 | Other | MO | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 2006005743 (Missouri) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas County Memorial Hospital | 9436041696 | 29 |
News Archive
More than 30 prominent international scientists gathered to discuss the state-of-the-art, as well as promising future approaches for the treatment of lung cancer at the stunning 17th century Borgo San Luigi, in Monteriggion, in the heart of the Tuscany countryside.
At least one in 10 athletes sustained an injury and a further one in 14 fell ill during the 2010 Winter Olympics, held in Canada, reveals research published in the British Journal of Sports Medicine.
The University of Texas MD Anderson Cancer Center and Nanobiotix today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers, with the first trials to be launched in 2019.
Forest Laboratories, Inc. Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH announced today that they have entered into settlement agreements with all remaining defendants in patent infringement litigation related to Forest's NAMENDA® (memantine hydrochloride) immediate release tablets.
The New York City Department of Health and Mental Hygiene (DOHMH) today reminded New Yorkers with asthma - who may be at risk of increased symptoms during allergy season - to practice good asthma management, including identifying and avoiding asthma triggers and taking appropriate medications as directed by a health care provider.
› Verified 9 days ago
| Entity Name | Texas County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306885587 PECOS PAC ID: 9436041696 Enrollment ID: O20040325000339 |
News Archive
More than 30 prominent international scientists gathered to discuss the state-of-the-art, as well as promising future approaches for the treatment of lung cancer at the stunning 17th century Borgo San Luigi, in Monteriggion, in the heart of the Tuscany countryside.
At least one in 10 athletes sustained an injury and a further one in 14 fell ill during the 2010 Winter Olympics, held in Canada, reveals research published in the British Journal of Sports Medicine.
The University of Texas MD Anderson Cancer Center and Nanobiotix today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers, with the first trials to be launched in 2019.
Forest Laboratories, Inc. Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH announced today that they have entered into settlement agreements with all remaining defendants in patent infringement litigation related to Forest's NAMENDA® (memantine hydrochloride) immediate release tablets.
The New York City Department of Health and Mental Hygiene (DOHMH) today reminded New Yorkers with asthma - who may be at risk of increased symptoms during allergy season - to practice good asthma management, including identifying and avoiding asthma triggers and taking appropriate medications as directed by a health care provider.
› Verified 9 days ago
| Entity Name | Texas County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285957001 PECOS PAC ID: 9436041696 Enrollment ID: O20100813000720 |
News Archive
More than 30 prominent international scientists gathered to discuss the state-of-the-art, as well as promising future approaches for the treatment of lung cancer at the stunning 17th century Borgo San Luigi, in Monteriggion, in the heart of the Tuscany countryside.
At least one in 10 athletes sustained an injury and a further one in 14 fell ill during the 2010 Winter Olympics, held in Canada, reveals research published in the British Journal of Sports Medicine.
The University of Texas MD Anderson Cancer Center and Nanobiotix today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers, with the first trials to be launched in 2019.
Forest Laboratories, Inc. Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH announced today that they have entered into settlement agreements with all remaining defendants in patent infringement litigation related to Forest's NAMENDA® (memantine hydrochloride) immediate release tablets.
The New York City Department of Health and Mental Hygiene (DOHMH) today reminded New Yorkers with asthma - who may be at risk of increased symptoms during allergy season - to practice good asthma management, including identifying and avoiding asthma triggers and taking appropriate medications as directed by a health care provider.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher O Baldwin, MD 1337 S Sam Houston Blvd, Houston, MO 65483-2046 Ph: (417) 967-5639 | Dr Christopher O Baldwin, MD 1337 S Sam Houston Blvd, Houston, MO 65483 Ph: (417) 967-5639 |
News Archive
More than 30 prominent international scientists gathered to discuss the state-of-the-art, as well as promising future approaches for the treatment of lung cancer at the stunning 17th century Borgo San Luigi, in Monteriggion, in the heart of the Tuscany countryside.
At least one in 10 athletes sustained an injury and a further one in 14 fell ill during the 2010 Winter Olympics, held in Canada, reveals research published in the British Journal of Sports Medicine.
The University of Texas MD Anderson Cancer Center and Nanobiotix today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers, with the first trials to be launched in 2019.
Forest Laboratories, Inc. Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH announced today that they have entered into settlement agreements with all remaining defendants in patent infringement litigation related to Forest's NAMENDA® (memantine hydrochloride) immediate release tablets.
The New York City Department of Health and Mental Hygiene (DOHMH) today reminded New Yorkers with asthma - who may be at risk of increased symptoms during allergy season - to practice good asthma management, including identifying and avoiding asthma triggers and taking appropriate medications as directed by a health care provider.
› Verified 9 days ago